In CLL cells, idelalisib abrogates the protective effect of many microenvironmental signals including CD40L, BAFF, TNFα, ET1, fibronectin adhesion as well as contact with stromal cells and NLC [38–40] (Fig. 1). This evidence concerns the gene CD40LG and B-cell chronic lymphocytic leukemia.